93Z Stock Overview
Marinomed Biotech AG, a biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Marinomed Biotech AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €16.55 |
| 52 Week High | €44.70 |
| 52 Week Low | €16.55 |
| Beta | -0.011 |
| 1 Month Change | -23.02% |
| 3 Month Change | -40.89% |
| 1 Year Change | -52.71% |
| 3 Year Change | -87.60% |
| 5 Year Change | -78.65% |
| Change since IPO | -77.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| 93Z | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -12.4% | 1.9% | 1.2% |
| 1Y | -52.7% | -28.2% | 2.0% |
Return vs Industry: 93Z underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: 93Z underperformed the German Market which returned 2% over the past year.
Price Volatility
| 93Z volatility | |
|---|---|
| 93Z Average Weekly Movement | 6.1% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 93Z's share price has been volatile over the past 3 months.
Volatility Over Time: 93Z's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 44 | Andreas Grassauer | www.marinomed.com |
Marinomed Biotech AG, a biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally. Its products pipeline includes Budesolv for the treatment of allergic rhinitis and autoimmune gastritis; Tacrosolv, which is in Phase II clinical trial for anterior inflammatory eye diseases; Carravin for the treatment of nasal congestion; and Inhaleen that is in Phase I clinical trial for viral pneumonia, as well as Carragelose, which consists of nasal and throat sprays, and lozenges for treating viral respiratory infections. The company was formerly known as Marinomed Biotechnologie GmbH and changed its name to Marinomed Biotech AG in June 2017.
Marinomed Biotech AG Fundamentals Summary
| 93Z fundamental statistics | |
|---|---|
| Market cap | €27.42m |
| Earnings (TTM) | -€6.79m |
| Revenue (TTM) | €9.18m |
3.0x
P/S Ratio-4.0x
P/E RatioIs 93Z overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 93Z income statement (TTM) | |
|---|---|
| Revenue | €9.18m |
| Cost of Revenue | €8.33m |
| Gross Profit | €856.80k |
| Other Expenses | €7.65m |
| Earnings | -€6.79m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 22, 2024
| Earnings per share (EPS) | -4.41 |
| Gross Margin | 9.33% |
| Net Profit Margin | -73.99% |
| Debt/Equity Ratio | -215.0% |
How did 93Z perform over the long term?
See historical performance and comparison